Solensia and Librela Cost 2026: Price per Injection, Side Effects and Does It Work

Updated: October 25, 2026 · Reading time: about 14 minutes · Prices from US and UK clinic price lists, insurer guides and cost surveys dated 2026

Solensia and Librela Cost 2026: Price per Injection for Cats and Dogs, Side Effects and Does It Work

Eylül Karaman

Pet health research · Checked against current FDA labels, FDA post-market communications, UK VMD safety updates and EMA product information. General education only; treatment decisions belong with your veterinarian.

How much do Solensia and Librela cost? 2026 prices

Both drugs are dosed by body weight, so the vial count drives the bill. Solensia comes as a 7 mg vial: cats of 2.5–7 kg get one, cats of 7–10 kg get two. Librela comes in 5, 10, 15, 20 and 30 mg vials matched to weight bands; dogs over 60 kg need two. On top of the drug, clinics add a markup, an administration fee and, at some practices, an exam fee each month.

Solensia cost for cats

Librela cost for dogs

Extras to budget for: an exam fee of $50–$100 where the clinic requires a vet rather than a nurse visit; a CBC and chemistry panel ($83–$228 and $104–$186 in published US invoices) before starting and periodically; X-rays ($149–$331) if the diagnosis has not been confirmed. Canada, Australia and the EU sit in a similar range in local currency, with wide clinic-to-clinic variation; the only reliable number is your own clinic's quote.

Ways to pay less

• Nurse-visit pricing. Many clinics let a nurse give the monthly injection after the first vet consultation; ask whether the exam fee drops out after month one.
• Corporate vs independent. Hospital chains tend to price at the top of the range; independent and mobile practices are often 20–30% lower for the same vial.
• Insurance. Accident-and-illness policies usually reimburse prescription drugs for a covered diagnosis (see below); wellness plans do not.
• Manufacturer rebates. Zoetis runs periodic rebate programmes through clinics in the US; ask whether one is active.
• Do not skip the reassessment. If there is no benefit after two or three doses, the cheapest option is to stop and revisit the plan, not to keep paying.

Does pet insurance cover Solensia and Librela?

Policy wording decides, not the brand. In general: an accident-and-illness policy reimburses prescription medications for a condition diagnosed after the waiting period, so osteoarthritis diagnosed on the policy is usually covered up to the annual limit after the deductible and co-pay. Arthritis signs recorded before enrolment make it a pre-existing condition, which is excluded by almost every insurer. Ask in writing whether the policy covers the specific drug, the monthly administration fee, chronic conditions year after year, and diagnostic monitoring.

How Solensia and Librela work

Nerve growth factor (NGF) drives pain signalling and sensitisation in osteoarthritic joints. Frunevetmab (Solensia) and bedinvetmab (Librela) are monoclonal antibodies engineered for cats and dogs respectively; they bind NGF and reduce its effect. They are analgesic therapies, with a different mechanism from NSAIDs, gabapentin or opioids: they target the NGF pathway rather than cyclooxygenase enzymes or general neural signalling.

Effectiveness: why "75% success" needs context

A success percentage means something only with the outcome definition, time point and control-group response.

Solensia

In one FDA field study, owner-rated (CSOM) success at day 56 was 75.1% with Solensia versus 64.8% with placebo; at day 84 it was 76.5% versus 67.3%. A second study showed 80.0% versus 47.1% at day 56. FDA has described the approval as a weight-of-evidence decision because chronic pain studies in cats are hard to run; one confirmatory study did not meet its protocol definition of success, but the overall evidence supported effectiveness.

Librela

At day 28, treatment success (CBPI) was 48.0% Librela vs 36.1% control in the US field study and 45.2% vs 17.0% in the EU study. The US day-28 primary comparison was not statistically significant; the EU study's was. From day 42 onward both studies showed more successes in the Librela group, and FDA concluded the evidence supports effectiveness when at least two monthly doses are given.

Solensia is a monthly subcutaneous injection; many clinics let a nurse administer it after the first veterinary consultation, which lowers the monthly fee.

Solensia safety: "no kidney concern" is too absolute

Frunevetmab is a protein broken down through normal catabolic pathways, not the cytochrome P450 system, which is why it is often suggested for cats that cannot take NSAIDs. That does not make it kidney-neutral. The US label's field study recorded renal insufficiency in 6.6% of Solensia-treated cats versus 4.3% of controls; the table does not prove causation, but it rules out a "zero renal concern" claim. In April 2026 EMA's veterinary committee recommended adding ataxia, polyuria and polydipsia as very rare adverse events (and rare anaphylaxis); the UK VMD implemented the same update in September 2026. FDA's adverse-event database also contains renal and neurologic reports; spontaneous reports flag signals but cannot establish incidence or causation.

Librela safety: the picture changed after approval

In December 2024 the FDA notified veterinarians that adverse-event reports included ataxia, seizures, paresis, recumbency, urinary incontinence, polyuria and polydipsia, with death or euthanasia reported as the outcome in some cases. In February 2025 the label gained a post-approval experience section and a Client Information Sheet telling owners to discuss balance problems, trouble standing or walking, seizures and urinary problems before treatment and to call the vet for any neurologic, urinary or gastrointestinal change. In 2026 the UK VMD added very rare paresis, paralysis and immune-mediated polyarthritis (February) and very rare joint swelling, joint pain, bone and joint disorders and soft-tissue ossification (May), advising diagnostics and case-by-case discontinuation when new joint swelling or pain appears.

Adverse-event reports are signals, not incidence rates

Spontaneous reports are easy to misuse. FDA states that not every reported event is caused by the drug, that one report may contain several signs, that reporting is incomplete and that the number of treated animals is unknown. Avoid statements like "X% of Librela dogs develop neurologic problems" unless a regulator or controlled study supports the figure.

Can Librela or Solensia be combined with NSAIDs or gabapentin?

US prescribing information for both products states that safe use with concurrent NSAIDs has not been established. Veterinarians do make individual multimodal decisions, including gabapentin for cats, but no combination protocol has label-level safety evidence. Treat online combination schedules as opinion.

Pick three to five everyday movements, film them before the first injection and before each monthly dose; that record decides whether the next $100 is worth paying.

Who should have a more detailed risk-benefit discussion?

How to judge whether the injections are helping

Frequently asked questions

Bottom line

Solensia and Librela are regulator-approved osteoarthritis pain treatments with evidence of benefit, and they cost roughly $100 a month for a cat or small dog and up to $300 a month for a giant dog in the US, around £100 in the UK. Some animals improve, some do not, and both products' safety information is still evolving. Get an all-in quote, record a mobility baseline, give at least two doses before judging, and reassess benefit and side effects every month.